Get the Stockscreener App
204.15
1.12%
2.27
After Hours:
204.15
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $204.15, with a volume of 1.03M.
It is up +1.12% in the last 24 hours and down -10.51% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$201.88
Open:
$200.54
24h Volume:
1.03M
Relative Volume:
0.91
Market Cap:
$29.61B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
19.68
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+2.71%
1M Performance:
-10.51%
6M Performance:
-17.09%
1Y Performance:
-18.89%
1-Day Range:
$200.25
$205.49
1-Week Range:
$200.00
$206.00
52-Week Range:
$198.61
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
204.15 | 29.28B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
439.92 | 149.15B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
142.35 | 39.53B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.97 | 31.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.02 | 30.60B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Integrated Investment Consultants LLC Invests $1.34 Million in ResMed Inc. $RMD - MarketBeat
Passumpsic Savings Bank Purchases New Stake in ResMed Inc. $RMD - MarketBeat
Should you continue to hold Resmed stock in your portfolio? - MSN
ResMed Inc. stock (US7611521078): dividend in focus after solid Q3 results - AD HOC NEWS
Why are ResMed shares lagging if the business keeps compounding? - MSN
Stephens Investment Management Group LLC Decreases Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MSN
With Strong Cash Flow, ResMed Stock Poised to Rise? - Trefis
Strong Cash Yield: Is ResMed Stock A Buy? - Trefis
ResMed Inc stock (US75102W1036): Noctrix deal, dividend and shifting sentiment put sleep-therapy spe - AD HOC NEWS
Arbejdsmarkedets Tillaegspension Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc stock (AU000000RMD6): Noctrix deal and market cap slide in focus - AD HOC NEWS
Needham reiterates Hold on ResMed stock on Noctrix acquisition By Investing.com - Investing.com South Africa
Needham reiterates Hold on ResMed stock on Noctrix acquisition - Investing.com
ResMed Inc. stock (US7611521078): earnings beat, dividend and softer 2026 share price - AD HOC NEWS
Bank Julius Baer & Co. Ltd Zurich Lowers Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Purchased by AustralianSuper Pty Ltd - MarketBeat
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
ResMed Inc stock (US75102W1036): Strong earnings offset by market underperformance - AD HOC NEWS
VIRGINIA RETIREMENT SYSTEMS ET Al Has $23.83 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed stock (US7611521078): Ex-dividend date arrives May 14 amid CEO option exercise - AD HOC NEWS
Swiss Life Asset Management Ltd Cuts Stake in ResMed Inc. $RMD - MarketBeat
ResMed, Inc.: - marketscreener.com
ResMed Inc stock (AU000000RMD6): ex-dividend date approaches May 14 - AD HOC NEWS
ResMed stock (US7611521078): ex-dividend date approaches on May 14 - AD HOC NEWS
ResMed stock (US7611521078): CEO exercises options amid NYSE price drop - AD HOC NEWS
RMD Stock Chart | RESMED INC (NYSE:RMD) - ChartMill
Is ResMed a Better Buy Than Stryker? - Trefis
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Should you buy ResMed shares at their 52-week low? - The Motley Fool Australia
ResMed stock hits 52-week low at $198.62 By Investing.com - Investing.com India
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.0 - GuruFocus
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.01 vs Price $198.76 - GuruFocus
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
ResMed stock hits 52-week low at $198.62 - Investing.com
ResMed Inc. stock (US7611521078): Recent price dynamics signal trading opportunities - AD HOC NEWS
ResMed (NYSE:RMD) CEO Sells $1,037,229.62 in Stock - MarketBeat
ResMed chairman and CEO Michael Farrell sells $1 million in stock - Investing.com UK
ResMed chairman and CEO Michael Farrell sells $1 million in stock By Investing.com - Investing.com South Africa
Resmed Insider Sold Shares Worth $1,037,233, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) CEO sells 4,991 shares under 10b5-1 plan - Stock Titan
ResMed Inc stock (AU000000RMD6): Sleep apnea and respiratory care leader posts strong growth outlook - AD HOC NEWS
ResMed (NYSE:RMD) Could Be A Buy For Its Upcoming Dividend - Yahoo Finance
ResMed Inc. stock: Earnings beat but shares slip on guidance concerns - AD HOC NEWS
Number of shareholders of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – LSX:935168 - TradingView
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Pharmaceuticals Sector Landscape - Markets Mojo
Mitsubishi UFJ Asset Management Co. Ltd. Increases Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Strs Ohio - MarketBeat
ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix deal - MSN
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):